GIreasons
Gastrointestinal Randomized Events And Safety Open-label NSAIDS Study

Pfizer Pharmaceuticals

This study is a six and half month study to collect data on outcomes of different treatments strategies within the setting of the US healthcare system.  Patients will be required to sign an informed consent and visit with Dr. Bruce Burtenshaw or study staff five times within six and half months.

We are looking for the following patients:

• Male or female 55 years and older.

• Patients that have been diagnosis with Osteoarthritis and are ready to be treated.

• Female CAN NOT be pregnant or breast feeding.

• Patients CAN NOT have a GI ulcer hemorrhage, active GD ulceration, a positive fecal occult blood test, history of heart attack, history of heart problems, history of stroke, or congestive heart failure.

• Patients CAN NOT have imflammatory bowel disease, renal insufficiency, cirrhosis of the liver, history of gastric or duodenal surgery other than patch repair, history of cancer, history of alcohol or drug abuse.

• Patients CAN NOT be using aspirin, lithium, any anticoagulants, or any antiplatelet therapy.

• Patients CAN NOT be hypersensitivity to celecoxib, NSAIDs, aspirin, and sulfonamides.

• Patients CAN NOT have a ALT or AST greater than 1.5 times the upper limit of normal, serum creatinine greater than 1.2 times the upper limit or normal, or Hb less than 11.5 g/dL.
  
  
  
  
  Back